Effect of Dry Needling on Insulin Resistance in Obese Post Menopausal Women (Dry needle)

January 23, 2026 updated by: Shymaa Mohammed Abdo Mohammed, Cairo University

Effect of Dry Needling on Insulin Resistance in Obese Post- Menopausal Women

The aim of the study is to determine the effect Dry Needling of on insulin resistance in obese postmenopausal women.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Insulin resistance and abdominal obesity have a negative impact on quality of life of postmenopausal women. Obesity and, more specifically, the level of intra-abdominal fat, are positively associated with cardiovascular disease and cardiovascular disease risk factors such as increased plasma lipids and lipoproteins, hyperinsulinemia, and insulin resistance. This study has shown associations among menopause, body fat, and body fat distribution, suggesting that increased abdominal fat distribution could partially mediate the increased cardiovascular disease risk of postmenopausal women .

Abdominal obesity can reflect excess of visceral fat tissue or subcutaneous or both. Visceral fat contributes to the pathogenesis of glucose intolerance and insulin resistance. Insulin resistance is an impaired condition of glucose absorption that induced by insulin .It represents a significant medical and socioeconomic issue impacting women's health and quality of life. So there is clinical experience and documentation for the effectiveness of Dry Needling in the treatment of insulin resistance in obese post-menopausal women.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
52

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Cairo, Egypt
        • Shymaa Mohammed

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • • All participants post-menopausal from at least 3 years.

    • All participants' ages will be ranged from 48-60 years old.
    • All participants BMI will exceed 25-30 kg/m2.
    • All participants waist hip ratio will be equal or more than 0, 90.

Exclusion Criteria:

  • • Surgical liposuction within the last 12 months.

    • Untreated hypo- or hyperthyroidism.
    • Uncontrolled liver, kidney or cardiovascular disease or diabetes.
    • Implanted pacemaker or metal implant.
    • History of thrombophlebitis, any hematological disease.
    • No past or present neurological and musculoskeletal disorders that will have affected health condition.
    • No smoking and drinking habits.
    • No psychological problems.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Dry Needle
26 patients who were treated with Dry Needling (three times /week/4 months), abdominal exercises, and medical standard care for insulin resistance.
Other: Dry Needle
Dry Needle has been used to treat obesity. Clinical research has found that it is particularly effective for abdominal fat loss.Dry needling in the abdominal region requires an in-depth understanding of the underlying anatomy due to significant safety risks.
Other: abdominal exercises, and medical standard care for insulin resistance
To reduce belly fat, combine core-strengthening exercises like planks, bicycle crunches, and leg raises with overall fat-burning cardio (walking, running) and a healthy diet
Other: abdominal exercises and medical standard care for insulin resistance.
While Group (B), 26 patients treated with abdominal exercises and medical standard care for insulin resistance.
Other: abdominal exercises, and medical standard care for insulin resistance
To reduce belly fat, combine core-strengthening exercises like planks, bicycle crunches, and leg raises with overall fat-burning cardio (walking, running) and a healthy diet

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
HOMA-IR
Time Frame: 4 months
Outcome measures, HOMA-IR (Homeostasis Model Assessment) will be used to assess insulin resistance. HOMA-IR is a model of interactions between glucose and insulin dynamics that is then used to predict fasting steady-state glucose and insulin concentrations for a wide range of possible combinations of insulin resistance and β-cell function.
4 months

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
ultrasound
Time Frame: 4 months
Abdominal fat thickness will be assessed by ultrasound (Aplio 500-model TUS-A500, fundamentals (2B77-004EN*M)
4 months
BMI by kg/m2
Time Frame: 4 months
weight and height will be combined to report BMI in kg/m^2
4 months
waist circumferences by tape
Time Frame: 4 months
4 months
The surface under the cumulative ranking curve (SUCRA)
Time Frame: 4 months
The surface under the cumulative ranking curve (SUCRA) was used to rank and compare the effects of different types of exercise. SUCRA values range from 0 to 100, where 100 indicates the best treatment with no uncertainty and 0 indicates the worst treatment with no uncertainty. Thus, higher SUCRA values indicated the better effects of an exercise intervention prior to and after four-month treatment duration for both groups.
4 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Cairo University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Shymaa Mohammed, out patient clinic ,faculty of physical therapy ,Cairo university ,Cairo,Egypt

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 1, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
April 1, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 1, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
December 14, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 23, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
January 26, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
January 26, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 23, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
January 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • P.T.REC/012/006055

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings